当前位置: X-MOL 学术J. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
The Journal of Infectious Diseases ( IF 6.4 ) Pub Date : 2020-07-09 , DOI: 10.1093/infdis/jiaa098
Steven K Grinspoon 1 , Pamela S Douglas 2 , Udo Hoffmann 3 , Heather J Ribaudo 4
Affiliation  

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible.

中文翻译:

利用人类免疫缺陷病毒初级心血管疾病预防的里程碑式试验:REPRIEVE 联合首席研究员的介绍。

预防 HIV 血管事件的随机试验 (REPRIEVE) 是最大型的人类免疫缺陷病毒心血管疾病研究。REPRIEVE 从 2015 年到 2019 年在五大洲招募了 7770 名参与者,将评估他汀类药物作为心血管疾病预防策略对接受抗逆转录病毒治疗 (ART) 的 HIV 感染者 (PWH) 的影响。尽管 REPRIEVE 及其评估冠状动脉斑块的子研究的主要目的是评估心血管结果,但该试验是关于 PWH 人群特征和严重合并症的丰富数据来源,特别是在全球疾病负担 (GBD) 地区,反映了这一全球流行病中的种族、种族和性别多样性。本补充的目的是利用 REPRIEVE 中丰富的表型,提供有关 GBD 区域基线 ART 和免疫功能的详细模式的数据、顺性别女性的生殖老化以及跨性别参与者的参与和临床特征的数据。我们还利用 REPRIEVE 评估严重的合并症,包括肾功能障碍、肌肉功能和虚弱以及心肌脂肪变性。REPRIEVE 是资助者、试验网络、临床研究地点、临床和数据协调中心以及愿意投入时间使试验成为可能的参与者之间的非凡合作。肌肉功能和虚弱,以及心肌脂肪变性。REPRIEVE 是资助者、试验网络、临床研究地点、临床和数据协调中心以及愿意投入时间使试验成为可能的参与者之间的非凡合作。肌肉功能和虚弱,以及心肌脂肪变性。REPRIEVE 是资助者、试验网络、临床研究地点、临床和数据协调中心以及愿意投入时间使试验成为可能的参与者之间的非凡合作。
更新日期:2020-07-09
down
wechat
bug